Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis
- PMID: 15173003
- DOI: 10.1158/0008-5472.CAN-03-2219
Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis
Abstract
Tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL) is a cytotoxic cytokine that induces apoptosis in tumor cells but rarely kills normal ones. To determine how normal human cells acquire TRAIL-sensitive phenotype during the process of malignant transformation, we used an experimental system that allows for controlled conversion of human cells from normal to cancerous by introduction of several genes. Human embryonic kidney cells and foreskin fibroblasts were first immortalized by combination of the early region of simian virus 40 and telomerase and then were transformed with oncogenic Ras. Both normal and immortalized cells were resistant to TRAIL-induced apoptosis, whereas Ras-transformed cells were susceptible. Ras transformation enhanced TRAIL-induced activation of caspase 8 by increasing its recruitment to TRAIL receptors. The proapoptotic effects of Ras could be reversed by mutations in its effector loop or by inhibitors of either farnesyl transferase or mitogen-activated protein kinase kinase. The expression of constitutively activated mitogen-activated protein kinase kinase 1 enhanced caspase 8 recruitment and sensitized immortalized human embryonic kidney cells to TRAIL-induced death. These results indicate that in normal human cells the TRAIL-induced apoptotic signal is blocked at the level of caspase 8 recruitment and that this block can be eliminated by Ras transformation, involving activation of the mitogen-activated protein kinase pathway.
Comment in
-
RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.Cancer Res. 2005 Feb 15;65(4):1615-6; author reply 1616-7. doi: 10.1158/0008-5472.CAN-04-2757. Cancer Res. 2005. PMID: 15735052 No abstract available.
Similar articles
-
Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.Clin Cancer Res. 2004 Oct 1;10(19):6650-60. doi: 10.1158/1078-0432.CCR-04-0576. Clin Cancer Res. 2004. PMID: 15475455
-
Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.Cancer Res. 2004 Nov 1;64(21):8036-44. doi: 10.1158/0008-5472.CAN-04-0762. Cancer Res. 2004. PMID: 15520213
-
Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.J Orthop Res. 2003 Sep;21(5):949-57. doi: 10.1016/S0736-0266(03)00062-7. J Orthop Res. 2003. PMID: 12919886
-
Mechanisms of resistance to TRAIL-induced apoptosis in cancer.Cancer Gene Ther. 2005 Mar;12(3):228-37. doi: 10.1038/sj.cgt.7700792. Cancer Gene Ther. 2005. PMID: 15550937 Review.
-
TRAIL and apoptosis induction by TNF-family death receptors.Oncogene. 2003 Nov 24;22(53):8628-33. doi: 10.1038/sj.onc.1207232. Oncogene. 2003. PMID: 14634624 Review.
Cited by
-
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations.Mol Cancer. 2010 Jul 30;9:203. doi: 10.1186/1476-4598-9-203. Mol Cancer. 2010. PMID: 20673328 Free PMC article.
-
TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.Cancers (Basel). 2022 Oct 19;14(20):5125. doi: 10.3390/cancers14205125. Cancers (Basel). 2022. PMID: 36291908 Free PMC article. Review.
-
H-Ras regulation of TRAIL death receptor mediated apoptosis.Oncotarget. 2014 Jul 15;5(13):5125-37. doi: 10.18632/oncotarget.2091. Oncotarget. 2014. PMID: 25026275 Free PMC article.
-
Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.Cytotherapy. 2015 Jul;17(7):885-96. doi: 10.1016/j.jcyt.2015.03.603. Epub 2015 Apr 14. Cytotherapy. 2015. PMID: 25888191 Free PMC article.
-
Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis.BMC Genomics. 2010 Mar 15;11:175. doi: 10.1186/1471-2164-11-175. BMC Genomics. 2010. PMID: 20230625 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous